Arthneeti
All Q2 FY26 results →
PD

Prevest Denpro Ltd

Q2 FY26Healthcare Equipment & Supplies

Prevest Denpro Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹405
Market cap₹458 Cr
P/E21.4
Updated23 Aug 2026
Read4 min read

The short version

Prevest DenPro expects to cross Rs. Prevest DenPro expects to cross Rs.

From Prevest Denpro Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Prevest DenPro expects to cross Rs. 100 crores in revenue within three years.
  • Current growth trajectory indicates a 15% year-on-year increase in top-line revenue.
  • For the financial year 2025-2026, an 18% cumulative growth has been achieved so far, with an anticipated 20% growth in the next half-year.
  • Domestic sales growth is expected to return to double digits following disruptions from GST changes and regional events.
  • U.S. market growth is strong, with a 43-47% increase in the first half year, expected to continue despite tariff adjustments.
  • Digital dentistry, including 3D printing solutions, disinfectants, and oral care products, is anticipated to drive significant future growth.

2 more points from Prevest Denpro Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Prevest Denpro Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • No significant new capital investments or expansion plans are currently anticipated.
  • The company has already made necessary investments to support expected sales growth.
  • Future expansion will be managed within existing budget thresholds without substantial additional expense.
  • Focus is on operational efficiencies and maintaining profitability rather than increasing operational expenses.
  • New product development and commercialization efforts are ongoing but do not currently require major capital outlay.

2 more points from Prevest Denpro Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Healthcare Equipment & Supplies

Ranked on what management guided this quarter

Guidance-ranked
1OSEL Devices
Rev 1Mar 3
2Avience Biomedi.
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 3
5
Rev 2Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Prevest Denpro Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided does not explicitly mention the current or expected order book or pending orders for Prevest DenPro Limited. However, the following points are relevant insights related to demand and order flow: - Export markets have shown strong growth with 24% increase in the first half of the financial year, indicating healthy order inflow from international customers. - U.S. market is growing well despite recent tariff issues, with private-label contracts and initial orders through their subsidiary Axiodent. - Domestic market saw a temporary slowdown due to external disruptions but shows recovery with double-digit growth expected in the second half. - The launch of new products like Rotoflex endodontic files and disinfectants are seeing good acceptance, suggesting continuing demand.

2 more points from Prevest Denpro Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Prevest Denpro Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹19 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Prevest Denpro's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

  • Aprameya Enginee (Q2 FY26)

    H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. Key investor presentation takeaways from Aprameya Engineering Ltd's Q2 FY26

  • Vaidya Sane (Q2 FY26)

    Ongoing construction and CAPEX of about INR 25-30 crores for capacity expansion at Khopoli and Nagpur hospitals. Key concall takeaways from Vaidya Sane's Q2…

  • Earkart (Q2 FY26)

    Earkart has already secured government orders worth approximately ₹9 crores in the current fiscal year (Page 8, 7th excerpt). Key concall takeaways from…

  • QMS Medical Allied Services Ltd (Q2 FY26)

    The only related transaction noted is the recent acquisition of Saarathi increasing stake from 51% to 76%, but no fundraising details were shared with respect…

Compare:vs Molbio Diagnostivs Poly Medicure Ltdvs Laxmi Dental Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Prevest Denpro Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Prevest Denpro Ltd Q2 FY26 results?

Prevest DenPro expects to cross Rs. Prevest DenPro expects to cross Rs.

What is Prevest Denpro Ltd share price analysis?

Prevest Denpro Ltd currently shows a neutral. The stock trades at a P/E of 21.4 with a market cap of ₹458 Cr. Investors should review the full earnings analysis for detailed insights.

Is Prevest Denpro Ltd planning capital expenditure?

No significant new capital investments or expansion plans are currently anticipated.

Keep Prevest Denpro Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.